1.02

0.00% 0.00

After Hours: 1.00 -0.02 -1.96%

Akebia Therapeutics Inc (AKBA)

Overview News Price History Option Chain Financials Discussions Forecast

Akebia Therapeutics Inc stock is traded at $1.02, with a volume of 2.32M. It is up +0.00% in the last 24 hours and down -28.17% over the past month. Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Previous Close:

$1.02

Open:

$1.01

24h Volume:

2.32M

Relative Volume:

0.66

Market Cap:

$273.62M

Revenue:

$236.20M

Net Income/Loss:

$-5.35M

P/E Ratio:

-56.98

EPS:

-0.0179

Net Cash Flow:

$67.70M

1W Performance:

-3.77%

1M Performance:

-28.17%

6M Performance:

-34.19%

1Y Performance:

-63.96%

1-Day Range:

$1.00

$1.05

1-Week Range:

$0.875

$1.0886

52-Week Range:

$0.875

$4.0787

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name

Akebia Therapeutics Inc

Sector

Healthcare (1108)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

617-871-2098

Address

245 FIRST STREET, CAMBRIDGE, MA

Employee

194

Twitter

@akebiatx

Next Earnings Date

2026-05-07

Latest SEC Filings

AKBA's Discussions on Twitter

Compare AKBA vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AKBA Akebia Therapeutics Inc	1.02	273.62M	236.20M	-5.35M	67.70M	-0.0179
TAK Takeda Pharmaceutical Co Adr	16.25	52.07B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.29	41.28B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.07	39.78B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	81.32	33.57B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	568.43	24.02B	3.17B	1.29B	1.01B	27.09

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-04-25	Resumed	H.C. Wainwright	Buy
Apr-28-25	Initiated	Leerink Partners	Outperform
Apr-01-25	Initiated	Jefferies	Buy
Nov-29-23	Resumed	BTIG Research	Buy
Aug-28-23	Upgrade	H.C. Wainwright	Neutral → Buy
May-31-23	Upgrade	Piper Sandler	Neutral → Overweight
Mar-31-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-22	Downgrade	Mizuho	Buy → Neutral
Mar-31-22	Downgrade	Needham	Buy → Hold
Mar-31-22	Downgrade	Piper Sandler	Overweight → Neutral
Mar-08-21	Initiated	Cantor Fitzgerald	Overweight
Jan-29-21	Downgrade	JP Morgan	Neutral → Underweight
Nov-14-19	Reiterated	Needham	Buy
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jul-11-19	Reiterated	H.C. Wainwright	Buy
May-02-19	Initiated	JP Morgan	Overweight
Mar-20-19	Initiated	Citigroup	Neutral
Sep-07-18	Resumed	Morgan Stanley	Equal-Weight
Aug-10-18	Reiterated	Needham	Buy
Jun-06-18	Reiterated	H.C. Wainwright	Buy
Dec-19-17	Initiated	Piper Jaffray	Overweight
Dec-07-17	Initiated	BTIG Research	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Sector Perform
Jul-10-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	H.C. Wainwright	Buy
Apr-27-17	Reiterated	Needham	Buy
Dec-27-16	Reiterated	H.C. Wainwright	Buy
Dec-20-16	Reiterated	JMP Securities	Mkt Outperform
Nov-15-16	Initiated	Aegis Capital	Buy
Sep-29-16	Initiated	Brean Capital	Buy
Mar-16-16	Reiterated	Needham	Buy
Jan-21-16	Initiated	Credit Suisse	Neutral

View All

Akebia Therapeutics Inc Stock (AKBA) Latest News

May 22, 2026

Earnings call transcript: Akebia Therapeutics Q1 2026 reports EPS miss, stock falls - Investing.com Canada

May 13, 2026

May 12, 2026

Korsana deal and cash crunch reshape Cyclerion (NASDAQ: CYCN) outlook - Stock Titan

May 12, 2026

State Street (AKBA) reports 11.6M-share, 4.3% stake in Akebia - Stock Titan

May 12, 2026

HC Wainwright Issues Negative Estimate for AKBA Earnings - MarketBeat

May 12, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

Akebia outlines phase II FSGS study of up to ~60 patients as Vafseo reaches nearly 7,500 patients - MSN

May 11, 2026

Here's What Analysts Are Forecasting For Akebia Therapeutics, Inc. (NASDAQ:AKBA) After Its First-Quarter Results - simplywall.st

May 11, 2026

Analysts Are Updating Their Akebia Therapeutics, Inc. (NASDAQ:AKBA) Estimates After Its First-Quarter Results - Yahoo Finance

May 11, 2026

Akebia Q1 2026 earnings preview - MSN

May 11, 2026

HC Wainwright Expects Lower Earnings for Akebia Therapeutics - MarketBeat

May 11, 2026

May 10, 2026

Akebia Therapeutics (AKBA) Is Down 14.5% After Swing To Q1 Loss And Share Increase Plan - Sahm

May 10, 2026

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Average Recommendation of "Hold" from Analysts - MarketBeat

May 10, 2026

May 09, 2026

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2026 Earnings Call Transcript - Insider Monkey

May 09, 2026

Akebia Therapeutics (AKBA) Receives a Buy from H.C. Wainwright - The Globe and Mail

May 09, 2026

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by Wall Street Zen - MarketBeat

May 09, 2026

May 08, 2026

Akebia Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo

May 08, 2026

Akebia Therapeutics(AKBA) Stock Options Chain | Quotes & News - Moomoo

May 08, 2026

H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo

May 08, 2026

Akebia (AKBA) Q1 2026 Earnings Transcript - AOL.com

May 08, 2026

Akebia Therapeutics, Inc. (NASDAQ:AKBA): Is Breakeven Near? - 富途牛牛

May 08, 2026

Q1 2026 Akebia Therapeutics Inc Earnings Call Transcript - GuruFocus

May 08, 2026

AKBA SEC FilingsAkebia Therapeut 10-K, 10-Q, 8-K Forms - Stock Titan

May 08, 2026

Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by Zacks Research - MarketBeat

May 08, 2026